Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950357 | 0.96 | TLR7 (0.83) | TLR7TLR8 | |
| SCHEMBL1615627 | 0.94 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL3863599 | 0.93 | TLR7 (0.98) | TLR7TLR8 | |
| SCHEMBL3970764 | 0.93 | TLR7 (0.94) | TLR7TLR8 | |
| SCHEMBL5122398 | 0.92 | TLR7 (0.91) | TLR7TLR8 | |
| SCHEMBL6053125 | 0.92 | TLR7 (0.79) | TLR7TLR8 | |
| SCHEMBL1951699 | 0.91 | TLR7 (0.93) | TLR7TLR8 | |
| SCHEMBL3863988 | 0.91 | TLR7 (0.81) | TLR7TLR8 | |
| SCHEMBL5352948 | 0.90 | TLR7 (0.72) | TLR7TLR8 | |
| SCHEMBL5618407 | 0.90 | TLR7 (0.72) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3589631-B1 | IMIDAZO[4,5-C]RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS | 3M INNOVATIVE PROPERTIES CO (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3344622-B1 | GUANIDINE SUBSTITUTED, FUSED 1H-IMIDAZO[4,5-C]PYRIDINE COMPOUNDS USEFUL IN THE TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES CO (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-108026092-B | Guanidine-substituted imidazo [4,5-c ] ring compounds | 3M创新有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10766896-B2 | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200108151-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200087298-A1 | Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2020-03-19 | — | — | US | disclosed |
| US-10487081-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | 3M INNOVATION PROPERTIES COMPANY (US) | 2019-11-26 | — | — | US | disclosed |
| EP-3554550-A1 | ANTIBODY ADJUVANT CONJUGATES | Bolt Biotherapeutics, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190055241-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2019-02-21 | — | — | US | disclosed |
| US-20190015516-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-7923560-B2 | Associated with typically attached to and, preferably, covalently attached to macromolecular support, e.g. a gel, foam, sponge, fiber, hydrogel, and a bead.; controlled drug delivery; retension of localized biological activity; toll-like receptors agonists to induce cytokine and interferon synthesis | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| EP-1617871-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS USING METAL-CONTAINING PARTICULATE SUPPORT MATERIALS | 3M Innovative Properties Company (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1615665-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M Innovative Properties Company (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040258698-A1 | Delivery of immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-23 | — | — | US | disclosed |
| WO-2004108072-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS USING METAL-CONTAINING PARTICULATE SUPPORT MATERIALS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004091500-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-14 | — | — | US | disclosed |
| EP-1187613-A4 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1187613-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000076505-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258698-A1 | Delivery of immune response modifier compounds | MIF, IRF3, CLEC4M | TLR7 126/4885TLR8 51/4885 |
| US-10487081-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | IFNG, IRF3, IL4 | TLR7 63/4885TLR8 211/4885 |
| US-20200087298-A1 | Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups | IL4, IFNG, IFNAR1 | TLR7 105/4885TLR8 213/4885 |
| US-20190015516-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | TLR7 121/4885TLR8 99/4885 |
| US-10766896-B2 | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups | IL4, IFNG, IFNAR1 | TLR7 105/4885TLR8 213/4885 |
| US-20200108151-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | TLR7 121/4885TLR8 99/4885 |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | MIF, IRF3, IRF2BP2 | TLR7 131/4885TLR8 99/4885 |
| US-20190055241-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IRF3, IL4 | TLR7 63/4885TLR8 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.